Is Royalty Pharma Stock a good buy in 2023, according to Wall Street analysts?
The consensus among 3 Wall Street analysts covering (NASDAQ: RPRX) stock is to Strong Buy RPRX stock.
Out of 3 analysts, 2 (66.67%) are recommending RPRX as a Strong Buy, 1 (33.33%) are recommending RPRX as a Buy, 0 (0%) are recommending RPRX as a Hold, 0 (0%) are recommending RPRX as a Sell, and 0 (0%) are recommending RPRX as a Strong Sell.
What is RPRX's forecast return on equity (ROE) for 2023-2026?
(NASDAQ: RPRX) forecast ROE is N/A, which is considered weak.
What is RPRX's Price Target?
According to 3 Wall Street analysts that have issued a 1 year RPRX price target, the average RPRX price target is $53.33, with the highest RPRX stock price forecast at $60.00 and the lowest RPRX stock price forecast at $48.00.
On average, Wall Street analysts predict that Royalty Pharma's share price could reach $53.33 by May 10, 2024. The average Royalty Pharma stock price prediction forecasts a potential upside of 59.58% from the current RPRX share price of $33.42.
What is RPRX's forecast return on assets (ROA) for 2023-2026?
(NASDAQ: RPRX) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.12%.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.